QOF Prevalence Health Check

Comparison August 2023 – August 2025                     Have you ever compared your list size/register sizes from one QOF year to another and looked at what effect this could have on the practice, especially...
Legacy Smartcard

Legacy Smartcard

This month there are changes to the smartcards used for signing electronic prescriptions. All relevant computers and devices must have the software Oberthur middleware installed. Middleware is the communications link between applications on a computer and the...
GLP-1 Notifications

GLP-1 Notifications

Judging by the number of private letters for patients commencing GLP-1 our coding team are getting currently, we imagine many of you are getting a bit bogged down by these.  The process we recommend is our coding team will add a code for anti-obesity medication...
Childhood Immunisations increased to £12.06

Childhood Immunisations increased to £12.06

To avoid confusion, the services listed below have increased from £10.06 to £12.06 per vaccine administered: Childhood Immunisations Hexavalent (6-in-1) vaccination programme 2025/28 (6IN125) HepB vaccination programme 2025/28 (HEPB25) Meningococcal B (MenB)...
Non-Diabetic Hyperglycaemia (NDH)

Non-Diabetic Hyperglycaemia (NDH)

NDH002 – % patients with NDH who have had a HbA1c or fasting glucose performed in the last 12m NDH or pre-diabetes is designed to intervene to prevent or delay the onset of type 2 diabetes. NDH has the fastest growing prevalence rate; 1.07% increase in the last...
Why do all items not appear on a FP34D Report?

Why do all items not appear on a FP34D Report?

If you add a code for administration of … and then add brand/manufacturer, it will not appear. For it to appear on the FP34D report it first needs to be added as a medicine to the patients acute list and have the box ticked for personally administered. This is really...
NHS Jewish BRCA testing programme

NHS Jewish BRCA testing programme

Launched in May, the NHS retrospective genetic testing programme provides genetic testing via R208/7 panels to people who have previously received a diagnosis of high grade non-mucinous epithelial ovarian cancer, triple negative breast cancer, or bilateral breast...